Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis

Lignende værker

• Teplizumab induces persistent changes in the antigen-specific repertoire in individuals at risk for type 1 diabetes
  af: Ana Lledó-Delgado, et al.
  Udgivet: (2024-09-01)
• Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 years
  af: Herold, Kevan C., et al.
  Udgivet: (2009)
• Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes
  af: Long, S. Alice, et al.
  Udgivet: (2016)
• Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial: Metabolic and Immunologic Features at Baseline Identify a Subgroup of Responders
  af: Herold, Kevan C., et al.
  Udgivet: (2013)
• An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes
  af: Herold, Kevan C., et al.
  Udgivet: (2019)